Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Holst JJ, rskov C, Vagn Nielsen O, Schwartz TW
Front Immunol (2017) 8:1632
Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations
These findings led to changes in clinical practice guidelines modern diabetes guidelines recommend GLP-1 agonists (or related drugs) for patients with type 2 diabetes who have cardiovascular risk, and even suggest using a GLP-1 RA prior to insulin in many cases due to their multiple benefits and weight loss advantage ( [10] ) ( [11] )
They allege manufacturers knew about these risks but downplayed the seriousness and failed to properly warn patients
PubMed laboratory research record [PMID: 7683357] PubMed record related to this compound for laboratory literature review
